Literature DB >> 8737152

Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci.

T M Coque1, K V Singh, B E Murray.   

Abstract

The in-vitro activities of the new fluoroquinolone trovafloxacin (CP-99,219) and ciprofloxacin were determined against 225 Gram-positive cocci. Trovafloxacin was 4-32 fold more active than ciprofloxacin against staphylococci and streptococci and also showed greater activity against enterococci including vancomycin resistant Enterococcus faecium and Enterococcus faecalis that were highly resistant to aminoglycosides and/or produced beta-lactamase. Trovafloxacin was also bactericidal at 3 mg/L against enterococci except for isolates for which the MICs were > or = 2 mg/L.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8737152     DOI： 10.1093/jac/37.5.1011

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  7 in total

1.  In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.

Authors:  E J Giamarellos-Bourboulis; H Sambatakou; P Grecka; H Giamarellou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-09       Impact factor: 3.267

2.  Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.

Authors:  H P Endtz; J W Mouton; J G den Hollander; N van den Braak; H A Verbrugh
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

3.  Activity of trovafloxacin (with or without ampicillin-sulbactam) against enterococci in an in vitro dynamic model of infection.

Authors:  S H Zinner; D Gilbert; M N Dudley
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

4.  In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique.

Authors:  L E Stearne; C Kooi; W H Goessens; I A Bakker-Woudenberg; I C Gyssens
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

5.  Antistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones.

Authors:  Alexander A Firsov; Irene Y Lubenko; Sergey N Vostrov; Yury A Portnoy; Stephen H Zinner
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

6.  Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography.

Authors:  A J Fischman; J W Babich; A A Bonab; N M Alpert; J Vincent; R J Callahan; J A Correia; R H Rubin
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

Review 7.  Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens.

Authors:  J C Pechère; T D Gootz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-06       Impact factor: 3.267
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.